Consensus Report
Astaxanthin
Strong Consensus
out of 5
Based on 11 videos (14 hours analyzed) across the experts · Updated 2026-03-23
Expert Positions
The Verdict
All 5 experts mention astaxanthin positively, but with varying depth and enthusiasm. Hyman provides the most extensive coverage through a dedicated interview on astaxanthin's longevity mechanisms. Patrick highlights its role as a potent antioxidant in krill oil and salmon roe that activates the FOXO3 longevity gene. Attia discusses ITP data showing a 10% lifespan increase in male mice but notes more dose-response research is needed. Huberman recommends it specifically for eye health and ocular blood flow. Johnson includes astaxanthin in his Blueprint supplement stack without detailed commentary.
Where They Disagree
Attia takes a notably more cautious stance than Hyman — while both reference the ITP data, Attia emphasizes the need for further dose-response studies and more rigorous human trials before making strong recommendations, whereas Hyman presents astaxanthin as a broadly beneficial longevity compound.
Huberman frames astaxanthin narrowly as an eye health supplement for macular support and ocular blood flow, while Hyman and Patrick highlight its systemic benefits across longevity pathways, brain health, and inflammation — reflecting different scopes of interest rather than disagreement.
+ 2 more disagreements in the full report
About This Analysis
This consensus report on Astaxanthin is based on 11 videos (14 hours analyzed) from five longevity experts: Andrew Huberman, Peter Attia, Rhonda Patrick, Bryan Johnson, and Mark Hyman. Each expert's position was independently analyzed from their published video content, including lectures, podcast episodes, and Q&A sessions with 1,000+ guest scientists.
The full report includes 8 key findings, dosage and protocol details, expert deep dives with direct video citations and timestamps, risk considerations, and related supplement synergies.
Frequently Asked Questions
What do experts agree on about astaxanthin?
All 5 experts mention astaxanthin positively, but with varying depth and enthusiasm. Hyman provides the most extensive coverage through a dedicated interview on astaxanthin's longevity mechanisms.
Where do the experts disagree on astaxanthin?
Attia takes a notably more cautious stance than Hyman — while both reference the ITP data, Attia emphasizes the need for further dose-response studies and more rigorous human trials before making strong recommendations, whereas Hyman presents astaxanthin as a broadly beneficial longevity compound. Huberman frames astaxanthin narrowly as an eye health supplement for macular support and ocular blood flow, while Hyman and Patrick highlight its systemic benefits across longevity pathways, brain health, and inflammation — reflecting different scopes of interest rather than disagreement. Patrick discusses astaxanthin primarily as a beneficial component of krill oil and salmon roe (food-first approach), while Hyman's coverage focuses on standalone supplementation — suggesting different philosophies on supplemental vs. dietary intake.
How strong is the expert consensus on astaxanthin?
The consensus on astaxanthin scores 3.7/5 — a strong level of agreement across Huberman, Attia, Patrick, Johnson, and Hyman, based on their public videos.
Related Reports
Unlock the Full Report
Get dosages, timing protocols, expert deep dives with video citations, and risks for Astaxanthin.
Every recommendation traces back to a specific expert, video, and timestamp.
$9/month or $79/year · Cancel anytime